Expect AZ To Hike Byetta's Price Ahead Of Teva's Generic

AstraZeneca PLC entered into a patent litigation settlement with Teva, giving the latter company the OK to market a generic version of Byetta (exenatide), a glucagon-like peptide-1 receptor agonist approved in the US to treat type 2 diabetes, beginning in October 2017. But before then, AstraZeneca is likely to hike Byetta's price – possible a few times.